Loading
Endometrial and Cervical Cancer Treatments / Colorectal and Anal Carcinomas · Journal article
Frontiers in Immunology · August 18, 2026
Encouraging direction, but not yet definitive.
This retrospective real-world study reports that cadonilimab 6 mg/kg every three weeks achieved an ORR of 55.6% and 12-month OS rate of 92.1% in 133 R/M cervical cancer patients treated as first-line therapy, with Grade ≥3 adverse events in 78.8% but rare severe immune-related events (3.6%). The results are encouraging but lack a prospective randomized comparator and prospective validation is required.
Retrospective real-world cohort study. Patients with recurrent or metastatic cervical cancer treated with cadonilimab as first-line therapy; includes subgroup analysis for patients aged ≥65 years.. Intervention: Cadonilimab 6 mg/kg intravenously every three weeks as first-line therapy. n = 133. Sichuan Cancer Center, China.
ORR was 55.6% (10.5% complete responses, 45.1% partial responses) in 133 efficacy-evaluable patients 12-month OS rate was 92.1% (95% CI, 86.5%-98.0%) 12-month PFS rate was 67.3% (95% CI, 58.4%-77.4%)
Grade ≥3 treatment-related adverse events occurred in 78.8%; immune-related adverse events in 35.0% with severe events in only 3.6%
The results suggest that low-dose cadonilimab may offer efficacy comparable to standard dosing with potentially improved cost accessibility for low- and middle-income settings. However, the lack of a control arm and retrospective design mean clinicians should await prospective randomized evidence before adopting dose reduction as standard practice.
A real-world retrospective study of adequate size showing encouraging efficacy (ORR 55.6%, 12-month OS 92.1%) with manageable toxicity in R/M cervical cancer, but lacking a control arm and requiring prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
The results suggest that low-dose cadonilimab may offer efficacy comparable to standard dosing with potentially improved cost accessibility for low- and middle-income settings. However, the lack of a control arm and retrospective design mean clinicians should await prospective randomized evidence before adopting dose reduction as standard practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background Cadonilimab, a bispecific PD-1/CTLA-4 antibody, has activity in recurrent/metastatic cervical cancer (R/M CC), but high costs limit accessibility, especially in low- and middle-income countries. Hence, we aimed to assess whether lower dose of cadonilimab may achieve comparable clinical outcomes with improved tolerability. Methods This retrospective real-world study evaluated 137 R/M CC patients treated with cadonilimab 6mg/kg every three weeks as first-line therapy at Sichuan Cancer center from January 1, 2023, to September 30, 2025. The primary endpoint was the objective response rate (ORR). Secondary endpoints included the disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. Results Among 133 efficacy-evaluable patients, the ORR was 55.6%, consisting of complete and partial responses in 10.5% and 45.1% of patients, respectively. The DCR was 83.5%. In patients aged ≥65 years, the ORR and DCR were 47.8% and 87.0%, respectively. The 12-month OS rate was 92.1% (95% CI, 86.5%-98.0%), and the 12-month PFS rate was 67.3% (95% CI, 58.4%-77.4%). Grade ≥3 treatment-related adverse events occurred in 78.8% and the most common were neutropenia, anemia, and lymphopenia. While immune-related adverse events were observed in 35.0% of patients, severe events were rare, occurring in only 3.6%. Furthermore, clinical outcomes and safety profiles were comparable across different chemotherapy regimens. Conclusions Low-dose cadonilimab demonstrates robust efficacy and manageable safety in R/M CC, with encouraging outcomes in elderly patients. Prospective randomized trials are needed to validate the efficacy of dose-reduced strategies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.